Charles J. Davidson

Charles J. Davidson

Auto-generated profile, based on publicly available information

Charles J. Davidson

Northwestern University Feinberg School of Medicine, Chicago, IL (C.J.D.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CDCharles J. Davidson
Charles J. Davidson
DLD. Scott Lim
D. Scott Lim
RSRobert L. Smith
Robert L. Smith
SKSusheel K. Kodali
Susheel K. Kodali
RKRobert M. Kipperman
Robert M. Kipperman
WGWilliam A. Gray
William A. Gray

29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
PLPhilipp Lurz
Philipp Lurz
RHRebecca T Hahn
Rebecca T Hahn
SKSusheel Kodali
Susheel Kodali
RMRaj Makkar
Raj Makkar
RSRahul P Sharma
Rahul P Sharma
VTVinod H Thourani
Vinod H Thourani
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.

1 March 2022 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
CDCharles J. Davidson
Charles J. Davidson
SASandra Abramson
Sandra Abramson
RSRobert L. Smith
Robert L. Smith
SKSusheel K. Kodali
Susheel K. Kodali
RKRobert M. Kipperman
Robert M. Kipperman
DLD. Scott Lim
D. Scott Lim

1 October 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
BDBrett F. Duncan
Brett F. Duncan
PMPatrick M. McCarthy
Patrick M. McCarthy
JKJane Kruse
Jane Kruse
AAAdin-Cristian Andrei
Adin-Cristian Andrei
ZLZhi Li
Zhi Li
SMS. Chris Malaisrie
S. Chris Malaisrie

3 June 2025 in Circulation
Verified
Journal Article
Open access
BLBrian R. Lindman
Brian R. Lindman
PPPhilippe Pibarot
Philippe Pibarot
ASAllan Schwartz
Allan Schwartz
JOJ. Bradley Oldemeyer
J. Bradley Oldemeyer
YSYan Ru Su
Yan Ru Su
PGPhilippe Généreux
Philippe Généreux
BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown. METHODS: A core laboratory measured NT-proBNP (N-terminal pro–B-type natriuretic peptide) and high-sensitivity cardiac troponin T (hs-cTnT) levels. Associations between biomarker levels and risk of the trial primary end point (death, stroke, or unplanned cardiovascular hospitalization) and other secondary end points were examined with Kaplan-Meier curves and Cox proportional hazard models. Interaction tests were performed to assess whether the treatment effect of early TAVR, compared with clinical surveillance, differed according to biomarker levels. RESULTS: Among 901 patients randomized in EARLY TAVR, 798 (89%) had biospecimens measured (median NT-proBNP level, 287 [145, 601]; median hs-cTnT level, 14.6 [10.5, 21.0]). Higher levels of NT-proBNP and hs-cTnT were broadly associated with higher event rates for multiple end points. In general, there was no significant interaction between baseline biomarkers and treatment group with respect to any composite or individual end point examined, although trends broadly demonstrated a greater relative benefit of early TAVR at lower biomarker levels. There was a significant interaction between hs-cTnT level and treatment group with respect to death or heart failure hospitalization ( P interaction =0.04) and heart failure hospitalization alone ( P interaction =0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. For some end points, higher baseline NT-proBNP level was associated with numerically greater absolute risk reduction with early TAVR than were lower NT-proBNP levels. CONCLUSIONS: In patients with asymptomatic severe high-gradient aortic stenosis, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates, as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in patients with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in asymptomatic patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03042104.

28 July 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
GPGraham Peigh
Graham Peigh
MAMohamed Al-Kazaz
Mohamed Al-Kazaz
LDLaura J. Davidson
Laura J. Davidson
MGMuhammed Gerçek
Muhammed Gerçek
MPMax Potratz
Max Potratz
CDCharles J. Davidson
Charles J. Davidson
In patients with a cardiac implantable electronic device (CIED) using a transvenous right ventricular (RV) lead, transcatheter tricuspid valve replacement (TTVR) results in RV lead entrapment. The authors sought to evaluate outcomes of patients with pre-existing transvenous RV leads undergoing EVOQUE TTVR. Patients with a CIED referred for TTVR at 3 centers were evaluated preoperatively by the heart team. Lead and clinical assessments were performed at baseline and in follow-up per local clinical practice. The primary outcome was the nature and incidence of major lead-related complications after TTVR. Secondary outcomes included changes in lead parameters after entrapment. Of 146 EVOQUE TTVR, 52 consecutive patients with entrapped RV leads (age 81 [77-85] years; 33 female patients (63.5%), lead dwell time 8.9 [3.3-13.6] years) were evaluated. Paravalvular leak was mild or less in 47 of 48 patients (98%) 30 days post-TTVR. Four patients had procedure-related lead complications: 1 intraprocedural RV lead dislodgement; 2 implantable cardioverter-defibrillator lead fractures 6- and 8-weeks post-TTVR; and 1 methicillin-resistant Staphylococcus aureus endocarditis 1 month post-TTVR. Among 46 complication-free patients with follow-up >30 days (356 [196-965] days), there were no other lead-related adverse events. Of the 33 patients without complications who had ≥1 CIED interrogation >30 days (424 [182-1,006] days) following TTVR, there was a significant decrease in lead impedance and increase in capture threshold on the final lead assessment, but no additional patients required lead revision. Following TTVR, most with entrapped RV leads remain free of lead-related complications. The need for urgent CIED revision due to RV lead dislodgment or failure is uncommon but may occur.